Neoleukin Therapeutics
Solebury Trout Talks: Interview with Jonathan Drachman, Neoleukin Therapeutics - Part of the Nametag Series
jonathan_egj86z.jpg

Itunes_kzba7m_75awwb_0.jpg

google_podcasts_badge2x_r3ddcn_c8dkjd_0.png

Jonathan is a seasoned clinician, researcher, and biopharmaceutical executive who joined Neoleukin at the company’s founding in 2018. For 14 years prior, he was at Seattle Genetics, where he most recently served as Chief Medical Officer and Executive Vice President of Research and Development. From 1998 to 2004, Dr. Drachman was a faculty member of the Division of Hematology at the University of Washington in Seattle, and a Senior Investigator in the Division of Research and Education at Puget Sound Blood Center. He currently serves on the board of directors for Calithera Biosciences and Harpoon Therapeutics. Dr. Drachman received a BA in Biochemistry from Harvard University and an MD from Harvard Medical School. He completed his residency in internal medicine and fellowship in medical oncology at the University of Washington.